EA202192607A1 - Композиции и способы для лечения глазного заболевания - Google Patents

Композиции и способы для лечения глазного заболевания

Info

Publication number
EA202192607A1
EA202192607A1 EA202192607A EA202192607A EA202192607A1 EA 202192607 A1 EA202192607 A1 EA 202192607A1 EA 202192607 A EA202192607 A EA 202192607A EA 202192607 A EA202192607 A EA 202192607A EA 202192607 A1 EA202192607 A1 EA 202192607A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
treatment
once
eye disease
Prior art date
Application number
EA202192607A
Other languages
English (en)
Inventor
Ниранджан Б. Пандей
Original Assignee
Асклепикс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Асклепикс Терапьютикс, Инк. filed Critical Асклепикс Терапьютикс, Инк.
Publication of EA202192607A1 publication Critical patent/EA202192607A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

В различных аспектах и вариантах реализации изобретения предложены способы и фармацевтические композиции для лечения глазного заболевания, связанного с сосудистой проницаемостью или воспалением глаз. В различных аспектах и вариантах реализации изобретение включает введение от около 1 мкг до около 1 мг биомиметического пептида, полученного из коллагена IV или его соли пациенту путем внутриглазной инъекции. Инъекции проводятся с частотой от около одного раза в месяц до около одного раза в два года. В различных вариантах реализации способы и композиции могут обеспечивать мощное действие и длительную продолжительность действия при нечастых интравитреальных инъекциях небольшого объема.
EA202192607A 2019-03-26 2020-03-26 Композиции и способы для лечения глазного заболевания EA202192607A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962824017P 2019-03-26 2019-03-26
PCT/US2020/024972 WO2020198481A1 (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease

Publications (1)

Publication Number Publication Date
EA202192607A1 true EA202192607A1 (ru) 2022-03-03

Family

ID=72609544

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192607A EA202192607A1 (ru) 2019-03-26 2020-03-26 Композиции и способы для лечения глазного заболевания

Country Status (12)

Country Link
US (1) US20230054032A1 (ru)
EP (1) EP3946418A4 (ru)
JP (1) JP2022527276A (ru)
KR (1) KR20210146352A (ru)
CN (1) CN113710264A (ru)
AU (1) AU2020248438A1 (ru)
CA (1) CA3134816A1 (ru)
EA (1) EA202192607A1 (ru)
IL (1) IL286625A (ru)
MX (1) MX2021011727A (ru)
WO (1) WO2020198481A1 (ru)
ZA (1) ZA202107235B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100144641A1 (en) * 2005-09-12 2010-06-10 Popel Aleksander S Compositions Having Antiangiogenic Activity and Uses Thereof
EP2649095B1 (en) * 2010-12-10 2021-10-06 Aleksander S. Popel Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
WO2014197892A1 (en) * 2013-06-07 2014-12-11 The Johns Hopkins University A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
US20180339024A1 (en) * 2015-11-19 2018-11-29 Asclepix Therapeutics, Llc Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
CN110177563A (zh) * 2016-10-04 2019-08-27 阿斯克雷佩西治疗公司 用于激活tie2信号传导的化合物和方法
AU2018266690A1 (en) * 2017-05-08 2019-12-12 Asclepix Therapeutics, Inc. Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
US11674959B2 (en) * 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors

Also Published As

Publication number Publication date
WO2020198481A1 (en) 2020-10-01
MX2021011727A (es) 2022-01-24
EP3946418A4 (en) 2023-02-22
ZA202107235B (en) 2023-10-25
AU2020248438A1 (en) 2021-10-28
CN113710264A (zh) 2021-11-26
KR20210146352A (ko) 2021-12-03
CA3134816A1 (en) 2020-10-01
JP2022527276A (ja) 2022-06-01
EP3946418A1 (en) 2022-02-09
US20230054032A1 (en) 2023-02-23
IL286625A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
JP2020528082A (ja) 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
JP2017515811A5 (ru)
ES2706059T3 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y derivado de L-arginina y una inyección que incluye la composición
RU2012140704A (ru) Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция
RU2006142861A (ru) Применение вязкоупругой композиции по новому назначению
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
NO980195L (no) Cyklosporinderivater med anti-HIV-effekt
WO2006119128A8 (en) Vascular targeting of ocular neovascularization
MX2021009526A (es) Composiciones para suministro farmacologico, para la administracion ocular de agentes terapeuticos, y metodos de uso de las mismas.
GB0716600D0 (en) Ophthalmic medicine composition
JP2018504984A5 (ru)
PH12021551232A1 (en) Haloallylamine compounds and application thereof
ES2672099T3 (es) Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
RU2018145017A (ru) Применение сиролимуса для лечения экссудативной возрастной макулярной дегенерации с персистирующим отеком
AU2016258001B2 (en) Injectable depot formulations
EA202192607A1 (ru) Композиции и способы для лечения глазного заболевания
AR123570A1 (es) Tratamientos para el edema macular diabético y la agudeza visual disminuida
MX2022003820A (es) Metodos de tratamiento para modificar la hermodinamica.
MX2021005077A (es) Peptidos y composiciones farmaceuticas para tratar enfermedades oculares.
EA202191130A1 (ru) Фармацевтическая композиция для лечения апластической анемии
RU2012127869A (ru) Устойчивые водные композиции пролекарств агонистов простагладина и способы их применения
JP6944463B2 (ja) 眼疾患の治療のための組成物及び方法
MX2022003051A (es) Formulaciones para la administracion de farmacos.
MX2021015796A (es) Composiciones y metodos para tratar enfermedades oculares.
MD722Z (ru) Устройство и метод лечения старческой катаракты